DNA X, Inc.
Income Statement
| Line Item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $16.2M | $11.2M | $16.7M | $15.0M | $15.0M | $11.5M | $16.8M | $13.4M |
| Cost of Revenue | $14.4M | $10.3M | $8.4M | $15.2M | $10.8M | $8.5M | $13.9M | $8.3M |
| Gross Profit | $1.8M | $845.0K | $8.4M | $-183.0K | $4.2M | $3.0M | $2.9M | $5.1M |
| Gross Margin | 11.2% | 7.6% | 50.0% | -1.2% | 28.2% | 25.8% | 17.3% | 38.1% |
| Operating Expenses | ||||||||
| Research & Development | $181.0K | $909.0K | $1.6M | $12.5M | $715.0K | $557.0K | $456.0K | — |
| SG&A Expense | $3.2M | $1.5M | $870.0K | $-4.8M | $2.8M | $2.4M | $2.6M | $2.4M |
| Operating Income | $-4.0M | $-1.5M | $-870.0K | $8.4M | $-2.4M | $-6.5M | $-2.7M | $-1.3M |
| Operating Margin | -24.5% | -13.1% | -5.2% | 56.3% | -15.8% | -56.2% | -16.0% | -9.3% |
| Interest Expense | $339.0K | $161.0K | $71.0K | — | — | — | — | — |
| Pretax Income | $-4.7M | $-1.9M | $-961.0K | $8.9M | $-2.4M | $-6.6M | $-2.8M | $-1.3M |
| Income Tax Expense | $90.0K | $138.0K | $132.0K | $-53.0K | $117.0K | $37.0K | $125.0K | $93.0K |
| Net Income | $-4.8M | $-7.5M | $458.0K | $-21.6M | $-2.5M | $-6.6M | $-2.9M | $-1.4M |
| Net Margin | -29.3% | -66.8% | 2.7% | -144.2% | -16.7% | -57.5% | -17.3% | -10.1% |
| EPS (Basic) | $-1.61 | $-4.72 | $0.47 | $-39.00 | $-3.11 | $-0.47 | $-0.22 | $-0.09 |
| EPS (Diluted) | $-1.61 | $-4.72 | $0.47 | $-39.00 | $-3.11 | $-0.47 | $-0.22 | $-0.09 |
| Shares Outstanding (Basic) | 3.0M | 1.6M | 973.3K | 786.4K | 808.2K | 14.1M | 13.3M | 12.9M |
| Shares Outstanding (Diluted) | 3.0M | 1.6M | 973.3K | 786.4K | 808.2K | 14.1M | 13.3M | 12.9M |
| Dividends Per Share | — | — | — | — | — | — | — | — |